Aliada Therapeutics的动态

Electrophysiology serves as a fundamental tool in the investigation of epilepsy, providing valuable insights into the underlying mechanisms of this complex neurological disorder. At EphyX Neuroscience, we routinely employ a range of epilepsy in vitro models including transgenic rodents and/or pharmacologically-induced epileptiform activity to test the effects of drug candidates. Below is a short example of what can be expected qualitatively from single cell recording of a CA1 pyramidal cell and pharmacological induction of epileptiform activity in P30 C57/Bl6 mouse acute brain slice using a combination of low magnesium and gabazine. The top panel (A) shows the spontaneous bursts of action potentials (APs) elicited in this condition compared to baseline standard ACSF. The bottom panel (B) shows the hyperexcitability of the cell when eliciting action potentials. Typical analysis would focus on the APs frequency, threshold, height and half-width but we adapt to your needs to extract and analyse the most relevant parameters for your project. Don't hesitate to contact us at [email protected]?to discuss your epilepsy research projects or if you would like to see more thorough sample data on the subject. #Electrophysiology #DrugDiscovery #CNSResearch #DrugDevelopment #PreclinicalResearch #ResearchAndDevelopment #Neurophysiology #CentralNervousSystem #Neuroscience #CRO #Pharma #ContractResearch #Epilepsy

#alhumdulillah I'm thrilled to announce the publication of our manuscript, "Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis," in CNS Neuroscience & Therapeutics (Impact Factor: 5.5). This study explores the critical role of non-coding RNAs in regulating autophagy processes, offering new insights into their potential as therapeutic targets for Parkinson's disease. Our findings highlight the complex interplay between these RNAs and the pathogenesis of Parkinson's, opening avenues for novel treatment strategies. A great thanks to all the co-authors (Professors) Mahamedha D., sachin singh, Kamal Dua, Vetriselvan Subramaniyan, Ph.D., FMSA., Access the full manuscript here: https://lnkd.in/gGDgy5p5 #Neuroscience #ParkinsonsDisease #Autophagy #NonCodingRNAs #Research #OpenAccess #CNSNeuroscienceTherapeutics

I’ll be presenting our first poster today on Neuroplastogen effects of psychedelics in neuronal primary cell cultures and the chronic mild stress model in rats, in collaboration with Gilgamesh Pharmaceuticals. If you’re interested in learning more about the effects of Ketamine and Psilocybin on PSD-95 Scholl Analysis and microtubule dynamics, come visit me! ?? Board B62 - Oct 5, 1-5 PM Poster title: “Plastinogenic Effects of Ketamine on Primary Mouse Cortical Neurons: Establishing a Platform for Novel Antidepressant Discovery” Ulysses Neuroscience Limited your Vanguard CRO and Translational Partner #Neuroscience #SfN2024 #Psychedelics #Neuroplasticity #Ketamine #Psilocybin #DepressionResearch #DrugDiscovery #CRO #SynapticPlasticity #MentalHealth

At EphyX Neuroscience we focus on in vitro electrophysiology for preclinical research and drug discovery in the Central Nervous System (CNS) area. Our mission is to empower our clients with the knowledge they need to make informed decisions about their compound selection by providing comprehensive insights into the mechanisms of action and neuronal physiology, using both rodent and human preparations. We understand that every research project is unique, which is why we offer customized solutions tailored to consider your specific needs and constraints. Whether you're looking to optimize your lead compound selection, understand the mechanism of action of a new drug, or investigate the physiological properties of neuronal networks, we have the expertise and technology to help you achieve your goals. #Electrophysiology #DrugDiscovery #CNSResearch #DrugDevelopment #PreclinicalResearch #ResearchAndDevelopment #Neurophysiology #CentralNervousSystem #Neuroscience #CRO #Pharma #ContractResearch

We're on the cusp of transformative breakthroughs in understanding and treating neurological disorders. Mirroring past accelerations in cardiology and oncology, decades of incremental advances, coupled with growing urgency due to rising global disease burdens, are driving progress. In this article, part of our recent New Medicines, Novel Insights report "Accelerating the new frontiers in neuroscience," Andreas Lysandropoulos, SVP - Global Therapeutic Area Head of Neuroscience at Parexel, highlights the challenges and immense opportunity in the clinical neuroscience landscape. Discover Andreas' insights on what is holding progress back and the drivers that will carry this critical research forward, revolutionizing patient care and treatment options. ??https://lnkd.in/eYS9WrSs #NovelInsights #Neuroscience #ClinicalResearch #PatientsFirst

Just Published: Our new Lab Note on performing Calcium Flux assays with our new iCell Sensory Neurons. Let me know if you want to discuss how our iCell Sensory Neurons can help your pain research

For my #neuroscience network ... Please give a follow to Spencer Knight he is a phenomenal resource for those of us who have been in the #neuroscience trenches...As a communicator, I've looked at the recent track record of Alzheimer's drugs There are No Silver Bullets! So we need to carefully communicate advances with healthcare professionals, patients, and caregivers as they have been burned very recently ... In 2001, Aducanumab was approved for treatment of Alzheimer’s disease.?Aduhelm? received accelerated approval as a treatment for Alzheimer's disease from the FDA. It was the first approved therapy to address the underlying biology of Alzheimer's disease. ·????????Aduhelm? will be discontinued on Nov. 1, 2024. In 2023, Lecanemab (Leqembi?) was approved by the FDA for the treatment of Alzheimer's disease.?It was approved as a treatment for early Alzheimer's by the FDA. It addresses the underlying biology of Alzheimer's and changes the course of the disease in a meaningful way for people in the early stages. In 2024, Donanemab (Kisunla?) was approved by the FDA for treatment of early Alzheimer's. It is the second approved treatment focused on the underlying biology of Alzheimer's and changes the course of the disease in a meaningful way for people in the early stages.

?? Early Registration Discount Alert! ?? Don't miss out on this exciting opportunity to save up to $760 by this Friday on your ticket to Hanson Wade's upcoming event in San Diego on Cell Therapy For Neurological Disorders. ?? Join experts from Aspen Neuroscience, Inc. Kenai Therapeutics, Coya Therapeutics, Inc., Inteligex, and UCSD as they share their latest innovations in developing safe and effective cell therapies for the CNS, aiming to elevate the standard of care for millions affected by neurological disorders. This December, our community will dive into key topics, including: ? Preclinical and clinical findings across various indications, such as ALS, MS, Alzheimer’s, and Parkinson’s. ? The pressing need for improved preclinical models to streamline the transition to clinical trials. ? Patient challenges, including immunosuppression, placebo effects, and the delivery of these therapies to the brain and nervous system. It’s a great opportunity for?you to?stay ahead?of?the curve?in neurodegenerative disease treatments. Our?agenda?provides an overview?of?what we have planned for this year’s event Full session details are available here: https://ter.li/h3ogz8 Register Here: https://lnkd.in/eY9_JEnN Email me at - [email protected] for any queries regarding this summit and our registration process. #Celltherapy #CellTherapyNeuro #CellTherapyForNeurologicalDisorders #ALS #MS #MultipleSclerosis #Parkinsons #Alzheimers #Stroke #Epilepsy

We're on the cusp of transformative breakthroughs in understanding and treating neurological disorders. Mirroring past accelerations in cardiology and oncology, decades of incremental advances, coupled with growing urgency due to rising global disease burdens, are driving progress. In this article, part of our recent New Medicines, Novel Insights report "Accelerating the new frontiers in neuroscience," Andreas Lysandropoulos MD, PhD highlights the challenges and immense opportunity in the clinical neuroscience landscape. Discover Andreas' insights on what is holding progress back and the drivers that will carry this critical research forward, revolutionizing patient care and treatment options. ?? https://lnkd.in/eBZV7vkU #NovelInsights #Neuroscience #ClinicalResearch #PatientsFirst?

We're on the cusp of transformative breakthroughs in understanding and treating neurological disorders. Mirroring past accelerations in cardiology and oncology, decades of incremental advances, coupled with growing urgency due to rising global disease burdens, are driving progress. In this article, part of our recent New Medicines, Novel Insights report "Accelerating the new frontiers in neuroscience," Andreas Lysandropoulos, SVP - Global Therapeutic Area Head of Neuroscience at Parexel, highlights the challenges and immense opportunity in the clinical neuroscience landscape. Discover Andreas' insights on what is holding progress back and the drivers that will carry this critical research forward, revolutionizing patient care and treatment options. ??https://lnkd.in/e6_2Y9HE #NovelInsights #Neuroscience #ClinicalResearch #PatientsFirst